{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028750","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.251042+00:00","generated_at":"2026-06-24T02:01:44.488475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022","bullets":["Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.","Cash and securities $788.2M as of June 30, 2022, extended runway into 2026.","Revenue fell to $0.5M from $2.2M, mainly due to wind-down of Neurocrine collaboration.","XEN1101 Phase 3 X-TOLE2 expected to start in H2 2022 after positive FDA End-of-Phase 2 meeting.","XEN496 EPIK study for KCNQ2-DEE anticipated to complete in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028750","json":"https://secwatch.observer/filing/0001564590-22-028750.json","markdown":"https://secwatch.observer/filing/0001564590-22-028750.md","text":"https://secwatch.observer/filing/0001564590-22-028750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/0001564590-22-028750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/xene-8k_20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:01:44.488475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}